medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2025-13-12-15medalphabet-4447Research ArticleСтатьиНеалкогольная жировая болезнь печени и пародонтит – клинико-патогенетические взаимосвязиNon-alcoholic fatty liver disease and periodontitis – clinical and pathogenetic relationshipshttps://orcid.org/0000-0002-7603-8481АхмедовВ. A.AkhmedovA. V.

Ахмедов Вадим Адильевич, д.м.н., проф., зав. кафедрой медицинской реабилитации дополнительного профессионального образования

Омск

Web of Science Researcher ID: AAU-3847-2020,

SCOPUS ID: 6603891660.

 

И DM Sci (habil.), professor, head of Dept of Medical Rehabilitation of Additional Professional Education

Omsk

Web of Science Researcher ID: AAU-3847-2020,

SCOPUS ID: 660389166

 

Omsk

v_akhmedov@mail.ruФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical UniversityRussian Federation202524072025013Гастроэнтерология и диетология (2)12=15Copyright © Ахмедов В.A., 20252025Ахмедов В.A.Akhmedov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4447

Неалкогольная жировая болезнь печени (НАЖБП) и пародонтит имеют ряд общих факторов риска, таких как ожирение, инсулинорезистентность (ИР) и дислипидемия, способствующих формированию системного воспаления. В представленной обзорной статье отмечено, что между НАЖБП и пародонтитом существует двунаправленная взаимосвязь, указывающая на то, что формирование одного заболевания может усугубить другое. НАЖБП на сегодняшний день рассматривается как системное воспаление, которое может способствовать прогрессированию пародонтита, нарушая иммунные реакции и усугубляя воспалительные процессы в тканях пародонта. У пациентов с НАЖБП часто наблюдается нарушение липидного обмена, которое может оказывать влияние на состав микробиоты полости рта, что приводит к дисбактериозу и повышенной восприимчивости к заболеваниям пародонта. И наоборот, пародонтит связан с прогрессированием НАЖБП через механизмы, включающие системное воспаление и окислительный стресс. Формирование хронического воспаления пародонта может сопровождаться выбросом провоспалительных цитокинов и бактериальных токсинов в кровоток, что способствует воспалению печени и усугубляет течение стеатоза печени. Взаимосвязь между НАЖБП и пародонтитом подчеркивает важность комплексных стратегий лечения, нацеленных на оба заболевания.

Non-alcoholic fatty liver disease (NAFLD) and periodontitis have a number of common risk factors, such as obesity, insulin resistance (IR), and dyslipidemia, which contribute to the formation of systemic inflammation. The review articles notes that there is a bidirectional relationship between NAFLD and periodontitis, indicating that the formation of one disease can worsen the other. Today, NAFLD is considered as a systemic inflammation that can contribute to the progression of periodontitis by disrupting immune responses and exacerbating inflammatory processes in periodontal tissues. Human patients with NAFLD often have impaired lipid metabolism, which can affect the composition of the oral microbiota, leading to dysbiosis and increased susceptibility to periodontal diseases. Conversely, periodontitis is associated with the progression of NAFLD through mechanisms including systemic inflammation and oxidative stress. The formation of chronic periodontal inflammation can be accompanied by the release of pro-inflammatory cytokines and bacterial toxins into the bloodstream, which contributes to liver inflammation and exacerbates the course of liver steatosis. The relationship between NAFLD and periodontitis highlights the importance of comprehensive treatment strategies targeting both diseases.

неалкогольная жировая болезнь печениинсулинорезистентностьсистемное воспалениепародонтитnon-alcoholic fatty liver diseaseinsulin resistancesystemic inflammationperiodontitisReferencesChen TP, Yu HC, Lin WY, Chang YC. The role of microbiome in the pathogenesis of oral-gut-liver axis between periodontitis and nonalcoholic fatty liver disease. J Dent Sci. 2023; 18: 972–975. DOI: 10.1016/j.jds.2023.03.012Chen TP, Yu HC, Lin WY, Chang YC. The role of microbiome in the pathogenesis of oral-gut-liver axis between periodontitis and nonalcoholic fatty liver disease. J Dent Sci. 2023; 18: 972–975. DOI: 10.1016/j.jds.2023.03.012Wadia R. Periodontitis and systemic inflammation. Br Dent J. 2022;233(6):494. DOI: 10.1038/s41415-022-5038-4Wadia R. Periodontitis and systemic inflammation. Br Dent J. 2022;233(6):494. DOI: 10.1038/s41415-022-5038-4Elghannam MT, Hassanien MH, Ameen YA. et al. Oral microbiome dysbiosis and gastrointestinal diseases: a narrative review. Egypt Liver J. 2024; 14: 32. DOI: 10.1186/s43066-024-00340-9Elghannam MT, Hassanien MH, Ameen YA. et al. Oral microbiome dysbiosis and gastrointestinal diseases: a narrative review. Egypt Liver J. 2024; 14: 32. DOI: 10.1186/s43066-024-00340-9Kobayashi R, Ogawa Y, Hashizume-Takizawa T, Kurita-Ochiai T. Oral bacteria affect the gut microbiome and intestinal immunity. Pathog Dis. 2020; 78 (3): ftaa024. DOI: 10.1093/femspd/ftaa024.Kobayashi R, Ogawa Y, Hashizume-Takizawa T, Kurita-Ochiai T. Oral bacteria affect the gut microbiome and intestinal immunity. Pathog Dis. 2020; 78 (3): ftaa024. DOI: 10.1093/femspd/ftaa024.Lei Y, Li S, He M. et al. Oral pathogenic bacteria and the oral-gut-liver axis: a new understanding of chronic liver diseases. Diagnostics (Basel). 2023; 13: 3324. DOI: 10.3390/diagnostics13213324Lei Y, Li S, He M. et al. Oral pathogenic bacteria and the oral-gut-liver axis: a new understanding of chronic liver diseases. Diagnostics (Basel). 2023; 13: 3324. DOI: 10.3390/diagnostics13213324Zhu X, Huang H, Zhao L. PAMPs and DAMPs as the Bridge Between Periodontitis and Atherosclerosis: The Potential Therapeutic Targets. Front Cell Dev Biol. 2022; 10: 856118. DOI: 10.3389/fcell.2022.856118.Zhu X, Huang H, Zhao L. PAMPs and DAMPs as the Bridge Between Periodontitis and Atherosclerosis: The Potential Therapeutic Targets. Front Cell Dev Biol. 2022; 10: 856118. DOI: 10.3389/fcell.2022.856118.Herwald H, Egesten A.J. On PAMPs and DAMPs. Innate Immun. 2016; 8 (5): 427–428. DOI: 10.1159/000448437.Herwald H, Egesten A.J. On PAMPs and DAMPs. Innate Immun. 2016; 8 (5): 427–428. DOI: 10.1159/000448437.Olofsson LE, Bäckhed F. The Metabolic Role and Therapeutic Potential of the Microbiome. Endocr Rev. 2022; 43 (5): 907–926. DOI: 10.1210/endrev/bnac004Olofsson LE, Bäckhed F. The Metabolic Role and Therapeutic Potential of the Microbiome. Endocr Rev. 2022; 43 (5): 907–926. DOI: 10.1210/endrev/bnac004Benedé-Ubieto R, Cubero FJ, Nevzorova YA.Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. 2024; 16 (1): 2331460. DOI: 10.1080/19490976.2024.2331460Benedé-Ubieto R, Cubero FJ, Nevzorova YA.Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. 2024; 16 (1): 2331460. DOI: 10.1080/19490976.2024.2331460Shen Y, Wu SD, Chen Y. et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. Gut Microbes. 2023; 15 (1): 2155018. DOI: 10.1080/19490976.2022.2155018Shen Y, Wu SD, Chen Y. et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. Gut Microbes. 2023; 15 (1): 2155018. DOI: 10.1080/19490976.2022.2155018Wang T, Ishikawa T, Sasaki M, Chiba T. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Porphyromonas gingivalis. Front Med (Lausanne). 2022; 9: 822190. DOI: 10.3389/fmed.2022.822190Wang T, Ishikawa T, Sasaki M, Chiba T. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Porphyromonas gingivalis. Front Med (Lausanne). 2022; 9: 822190. DOI: 10.3389/fmed.2022.822190Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. World J Gastroenterol. 2023; 29 (6): 967–996. DOI: 10.3748/wjg.v29.i6.967Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. World J Gastroenterol. 2023; 29 (6): 967–996. DOI: 10.3748/wjg.v29.i6.967Kuroe K, Furuta M, Takeuchi K, et al.: Association between periodontitis and fibrotic progression of nonalcoholic fatty liver among Japanese adults. J Clin Periodontol. 2021; 48: 368–377. DOI: 10.1111/jcpe.13415Kuroe K, Furuta M, Takeuchi K, et al.: Association between periodontitis and fibrotic progression of nonalcoholic fatty liver among Japanese adults. J Clin Periodontol. 2021; 48: 368–377. DOI: 10.1111/jcpe.13415Schwenger KJP, Sharma D, Ghorbani Y. et al. Links between gut microbiome, metabolome, clinical variables and non-alcoholic fatty liver disease severity in bariatric patients. Liver Int. 2024; 44 (5): 1176–1188. DOI: 10.1111/liv.15864Schwenger KJP, Sharma D, Ghorbani Y. et al. Links between gut microbiome, metabolome, clinical variables and non-alcoholic fatty liver disease severity in bariatric patients. Liver Int. 2024; 44 (5): 1176–1188. DOI: 10.1111/liv.15864Dou J, Chen X, Zhang J. et al. P. Gingivalis induce macrophage polarization by regulating hepcidin expression in chronic apical periodontitis. Int Immunopharmacol. 2024; 142 (Pt A): 113139. DOI: 10.1016/j.intimp.2024.113139Dou J, Chen X, Zhang J. et al. P. Gingivalis induce macrophage polarization by regulating hepcidin expression in chronic apical periodontitis. Int Immunopharmacol. 2024; 142 (Pt A): 113139. DOI: 10.1016/j.intimp.2024.113139Yuan K, Xu S, Liu G. et al. Porphyromonas gingivalis Promotes Oral Squamous Cell Carcinoma Progression by Modulating Autophagy. Oral Dis. 2025; 31 (2): 492–502. DOI: 10.1111/odi.15157Yuan K, Xu S, Liu G. et al. Porphyromonas gingivalis Promotes Oral Squamous Cell Carcinoma Progression by Modulating Autophagy. Oral Dis. 2025; 31 (2): 492–502. DOI: 10.1111/odi.15157Vegda HS, Patel B, Girdhar GA. Et al. Role of Nonalcoholic Fatty Liver Disease in Periodontitis: A Bidirectional Relationship. Cureus. 2024; 16 (7): e63775. DOI: 10.7759/cureus.63775Vegda HS, Patel B, Girdhar GA. Et al. Role of Nonalcoholic Fatty Liver Disease in Periodontitis: A Bidirectional Relationship. Cureus. 2024; 16 (7): e63775. DOI: 10.7759/cureus.63775Selvaraj EA, Mózes FE, Jayaswal AN, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021; 75: 770–785. DOI: 10.1016/j.jhep.2021.04.044Selvaraj EA, Mózes FE, Jayaswal AN, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021; 75: 770–785. DOI: 10.1016/j.jhep.2021.04.044Oka I, Shigeishi H, Ohta K. Co-Infection of Oral Candida albicans and Porphyromonas gingivalis Is Associated with Active Periodontitis in Middle-Aged and Older Japanese People. Medicina (Kaunas). 2022; 58 (6): 723. DOI: 10.3390/medicina58060723Oka I, Shigeishi H, Ohta K. Co-Infection of Oral Candida albicans and Porphyromonas gingivalis Is Associated with Active Periodontitis in Middle-Aged and Older Japanese People. Medicina (Kaunas). 2022; 58 (6): 723. DOI: 10.3390/medicina58060723Yamazaki K. Oral-gut axis as a novel biological mechanism linking periodontal disease and systemic diseases: a review. Jpn Dent Sci Rev. 2023; 59: 273–280. DOI: 10.1016/j.jdsr.2023.08.003Yamazaki K. Oral-gut axis as a novel biological mechanism linking periodontal disease and systemic diseases: a review. Jpn Dent Sci Rev. 2023; 59: 273–280. DOI: 10.1016/j.jdsr.2023.08.003Yao C, Lan D, Li X. et al. Porphyromonas gingivalis is a risk factor for the development of nonalcoholic fatty liver disease via ferroptosis. Microbes Infect. 2023; 25: 105040. DOI: 10.1016/j.micinf.2022.105040Yao C, Lan D, Li X. et al. Porphyromonas gingivalis is a risk factor for the development of nonalcoholic fatty liver disease via ferroptosis. Microbes Infect. 2023; 25: 105040. DOI: 10.1016/j.micinf.2022.105040Rinčić G, Gaćina P, Virović Jukić L. et al. Association between periodontitis and liver disease. Acta Clin Croat. 2022; 60: 510–518. DOI: 10.20471/acc.2021.60.03.22Rinčić G, Gaćina P, Virović Jukić L. et al. Association between periodontitis and liver disease. Acta Clin Croat. 2022; 60: 510–518. DOI: 10.20471/acc.2021.60.03.22Kiryowa HM, Munabi IG, Buwembo W. et al. Periodontitis is associated with insulin resistance in adults living with diabetes mellitus in Uganda: a cross- sectional study. BMC Res Notes. 2023; 16: 217. DOI: 10.1186/s13104-023-06473-1Kiryowa HM, Munabi IG, Buwembo W. et al. Periodontitis is associated with insulin resistance in adults living with diabetes mellitus in Uganda: a cross- sectional study. BMC Res Notes. 2023; 16: 217. DOI: 10.1186/s13104-023-06473-1Pussinen PJ, Kopra E, Pietiäinen M. et al. Periodontitis and cardiometabolic disorders: the role of lipopolysaccharide and endotoxemia. Periodontol 2000. 2022; 89: 19–40. DOI: 10.1111/prd.12433Pussinen PJ, Kopra E, Pietiäinen M. et al. Periodontitis and cardiometabolic disorders: the role of lipopolysaccharide and endotoxemia. Periodontol 2000. 2022; 89: 19–40. DOI: 10.1111/prd.12433Xu T, Liu R, Zhu H. et al. The inhibition of LPS-induced oxidative stress and inflammatory responses is associated with the protective effect of (–)-epigallocatechin 3-gallate on bovine hepatocytes and murine liver. Antioxidants (Basel). 2022; 11: 914. DOI: 10.3390/antiox11050914Xu T, Liu R, Zhu H. et al. The inhibition of LPS-induced oxidative stress and inflammatory responses is associated with the protective effect of (–)-epigallocatechin 3-gallate on bovine hepatocytes and murine liver. Antioxidants (Basel). 2022; 11: 914. DOI: 10.3390/antiox11050914Geng X, Xia X, Liang Z. et al. Tropomodulin1 exacerbates inflammatory response in macrophages by negatively regulating LPS-induced TLR4 endocytosis. Cell Mol Life Sci. 2024; 81 (1): 402. DOI: 10.1007/s00018-024-05424-8Geng X, Xia X, Liang Z. et al. Tropomodulin1 exacerbates inflammatory response in macrophages by negatively regulating LPS-induced TLR4 endocytosis. Cell Mol Life Sci. 2024; 81 (1): 402. DOI: 10.1007/s00018-024-05424-8Nakahara T, Hyogo H, Ono A. et al. Involvement of Porphyromonas gingivalis in the progression of nonalcoholic fatty liver disease. J Gastroenterol. 2018; 53: 269–280. DOI: 10.1007/s00535-017-1368-4Nakahara T, Hyogo H, Ono A. et al. Involvement of Porphyromonas gingivalis in the progression of nonalcoholic fatty liver disease. J Gastroenterol. 2018; 53: 269–280. DOI: 10.1007/s00535-017-1368-4Kamata Y, Kessoku T, Shimizu T. et al. Periodontal treatment and usual care for nonalcoholic fatty liver disease: a multicenter, randomized controlled trial. Clin Transl Gastroenterol. 2022; 13: e00520. DOI: 10.14309/ctg.0000000000000520Kamata Y, Kessoku T, Shimizu T. et al. Periodontal treatment and usual care for nonalcoholic fatty liver disease: a multicenter, randomized controlled trial. Clin Transl Gastroenterol. 2022; 13: e00520. DOI: 10.14309/ctg.0000000000000520Kobayashi T, Iwaki M, Nogami A. et al. Involvement of periodontal disease in the pathogenesis and exacerbation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: a review. Nutrients. 2023; 15: 1269. DOI: 10.3390/nu15051269Kobayashi T, Iwaki M, Nogami A. et al. Involvement of periodontal disease in the pathogenesis and exacerbation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: a review. Nutrients. 2023; 15: 1269. DOI: 10.3390/nu15051269Ishikawa M, Yoshida K, Okamura H. et al. Oral Porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen synthesis through the Akt/GSK 3β signaling pathway. Biochim Biophys Acta 2013; 1832: 2035–2043. DOI: 10.1016/j.bbadis.2013.07.012Ishikawa M, Yoshida K, Okamura H. et al. Oral Porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen synthesis through the Akt/GSK 3β signaling pathway. Biochim Biophys Acta 2013; 1832: 2035–2043. DOI: 10.1016/j.bbadis.2013.07.012Takamura H, Yoshida K, Okamura H. et al. Porphyromonas gingivalis attenuates the insulin-induced phosphorylation and translocation of forkhead box protein O1 in human hepatocytes. Arch Oral Biol 2016; 69: 19–24. DOI: 10.1016/j.archoralbio.2016.05.010Takamura H, Yoshida K, Okamura H. et al. Porphyromonas gingivalis attenuates the insulin-induced phosphorylation and translocation of forkhead box protein O1 in human hepatocytes. Arch Oral Biol 2016; 69: 19–24. DOI: 10.1016/j.archoralbio.2016.05.010Zaitsu Y, Iwatake M, Sato K, Tsukuba T. Lipid droplets affect elimination of Porphyromonas gingivalis in HepG2 cells by altering the autophagy-lysosome system. Microbes Infect 2016; 18: 565–571. DOI: 10.1016/j.micinf.2016.05.004Zaitsu Y, Iwatake M, Sato K, Tsukuba T. Lipid droplets affect elimination of Porphyromonas gingivalis in HepG2 cells by altering the autophagy-lysosome system. Microbes Infect 2016; 18: 565–571. DOI: 10.1016/j.micinf.2016.05.004Nagasaki A, Sakamoto S, Chea C. et al. Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation. Sci Rep. 2020; 10: 4134. DOI: 10.1038/s41598-020-60904-8Nagasaki A, Sakamoto S, Chea C. et al. Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation. Sci Rep. 2020; 10: 4134. DOI: 10.1038/s41598-020-60904-8Masi S, Gkranias N, Li K. et al. Association between short leukocyte telomere length, endotoxemia, and severe periodontitis in people with diabetes: a cross-sectional survey. Diabetes Care 2014; 37: 1140–1147. DOI: 10.2337/dc13-2106Masi S, Gkranias N, Li K. et al. Association between short leukocyte telomere length, endotoxemia, and severe periodontitis in people with diabetes: a cross-sectional survey. Diabetes Care 2014; 37: 1140–1147. DOI: 10.2337/dc13-2106Zbinden A, Bostanci N. Belibasakis GN. The novel species Streptococcus tigurinus and its association with oral infection. Virulence. 2015; 6(3):177–82. DOI:10.4161/21505594.2014.970472.Zbinden A, Bostanci N. Belibasakis GN. The novel species Streptococcus tigurinus and its association with oral infection. Virulence. 2015; 6(3):177–82. DOI:10.4161/21505594.2014.970472.Raja M, Ummer F, Dhivakar CP Aggregatibacter actinomycetemcomitans-a tooth killer? J Clin Diagn Res. 2014; 8: ZE13–6. DOI:10.7860/JCDR/2014/9845.4766Raja M, Ummer F, Dhivakar CP Aggregatibacter actinomycetemcomitans-a tooth killer? J Clin Diagn Res. 2014; 8: ZE13–6. DOI:10.7860/JCDR/2014/9845.4766Komazaki R, Katagiri S, Takahashi H. et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. Sci Rep. 2017; 7: 13950. DOI: 10.1038/s41598-017-14260-9Komazaki R, Katagiri S, Takahashi H. et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. Sci Rep. 2017; 7: 13950. DOI: 10.1038/s41598-017-14260-9Ozuna H, Snider I, Belibasakis GN. Aggregatibacter actinomycetemcomitans and Filifactor alocis: two exotoxin-producing oral pathogens. Front Oral Health. 2022; 3: 981343. DOI: 10.3389/froh.2022.981343Ozuna H, Snider I, Belibasakis GN. Aggregatibacter actinomycetemcomitans and Filifactor alocis: two exotoxin-producing oral pathogens. Front Oral Health. 2022; 3: 981343. DOI: 10.3389/froh.2022.981343Tan X, Wang Y, Gong T. The interplay between oral microbiota, gut microbiota and systematic diseases. J Oral Microbiol. 2023;15: 2213112. DOI: 10.1080/20002297.2023.2213112Tan X, Wang Y, Gong T. The interplay between oral microbiota, gut microbiota and systematic diseases. J Oral Microbiol. 2023;15: 2213112. DOI: 10.1080/20002297.2023.2213112Vliex LM, Penders J, Nauta A. et al. The individual response to antibiotics and dietinsights into gut microbial resilience and host metabolism. Nat Rev Endocrinol. 2024; 20: 387–398. DOI: 10.1038/s41574-024-00966-0Vliex LM, Penders J, Nauta A. et al. The individual response to antibiotics and dietinsights into gut microbial resilience and host metabolism. Nat Rev Endocrinol. 2024; 20: 387–398. DOI: 10.1038/s41574-024-00966-0Jeong SH, Nam Y, Jung H. et al. Interrupting oral infection of Porphyromonas gingivalis with anti-FimA antibody attenuates bacterial dissemination to the arthritic joint and improves experimental arthritis. Exp Mol Med 2018; 50: 1–2. DOI: 10.1038/s12276-018-0140-zJeong SH, Nam Y, Jung H. et al. Interrupting oral infection of Porphyromonas gingivalis with anti-FimA antibody attenuates bacterial dissemination to the arthritic joint and improves experimental arthritis. Exp Mol Med 2018; 50: 1–2. DOI: 10.1038/s12276-018-0140-zCai J, Chen J, Guo H. et al. Recombinant fimbriae protein of Porphyromonas gingivalis induces an inflammatory response via the TLR4/NFκB signaling pathway in human peripheral blood mononuclear cells. Int J Mol Med 2019; 43: 1430–1440. DOI: 10.3892/ijmm.2019.4069Cai J, Chen J, Guo H. et al. Recombinant fimbriae protein of Porphyromonas gingivalis induces an inflammatory response via the TLR4/NFκB signaling pathway in human peripheral blood mononuclear cells. Int J Mol Med 2019; 43: 1430–1440. DOI: 10.3892/ijmm.2019.4069Dominy SS, Lynch C, Ermini F. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with smallmolecule inhibitors. Sci Adv 2019; 5: eaau3333. DOI: 10.1126/sciadv.aau3333Dominy SS, Lynch C, Ermini F. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with smallmolecule inhibitors. Sci Adv 2019; 5: eaau3333. DOI: 10.1126/sciadv.aau3333Amini-Salehi E, Hassanipour S, Keivanlou MH. The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis. Nutr Rev. 2024; 82 (6): 815–830. DOI: 10.1093/nutrit/nuad086Amini-Salehi E, Hassanipour S, Keivanlou MH. The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis. Nutr Rev. 2024; 82 (6): 815–830. DOI: 10.1093/nutrit/nuad086

The authors declare that there are no conflicts of interest present.